EP2416807A4 - Nouvelles stratégies d'amélioration des vaccins anticancéreux - Google Patents

Nouvelles stratégies d'amélioration des vaccins anticancéreux

Info

Publication number
EP2416807A4
EP2416807A4 EP10762283A EP10762283A EP2416807A4 EP 2416807 A4 EP2416807 A4 EP 2416807A4 EP 10762283 A EP10762283 A EP 10762283A EP 10762283 A EP10762283 A EP 10762283A EP 2416807 A4 EP2416807 A4 EP 2416807A4
Authority
EP
European Patent Office
Prior art keywords
cancer vaccines
novel strategies
improved cancer
improved
strategies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP10762283A
Other languages
German (de)
English (en)
Other versions
EP2416807A1 (fr
Inventor
Chien-Hsing Chang
David M Goldenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immunomedics Inc
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/544,476 external-priority patent/US7901680B2/en
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Publication of EP2416807A1 publication Critical patent/EP2416807A1/fr
Publication of EP2416807A4 publication Critical patent/EP2416807A4/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001124—CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP10762283A 2009-04-10 2010-04-06 Nouvelles stratégies d'amélioration des vaccins anticancéreux Ceased EP2416807A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16829009P 2009-04-10 2009-04-10
US12/544,476 US7901680B2 (en) 2005-10-19 2009-08-20 Dock-and-lock (DNL) vaccines for cancer therapy
PCT/US2010/030045 WO2010117984A1 (fr) 2009-04-10 2010-04-06 Nouvelles stratégies d'amélioration des vaccins anticancéreux

Publications (2)

Publication Number Publication Date
EP2416807A1 EP2416807A1 (fr) 2012-02-15
EP2416807A4 true EP2416807A4 (fr) 2012-06-13

Family

ID=42936524

Family Applications (1)

Application Number Title Priority Date Filing Date
EP10762283A Ceased EP2416807A4 (fr) 2009-04-10 2010-04-06 Nouvelles stratégies d'amélioration des vaccins anticancéreux

Country Status (2)

Country Link
EP (1) EP2416807A4 (fr)
WO (1) WO2010117984A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107786A2 (fr) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Structures ameliorees, attachees de façon stable, de compositions definies presentant diverses fonctions ou specificites de liaison
WO2010022225A1 (fr) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Vaccins d'accostage et de verrouillage « dock-and-lock » (dnl) pour une thérapie contre le cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7527787B2 (en) * 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006107786A2 (fr) * 2005-04-06 2006-10-12 Ibc Pharmaceuticals, Inc. Structures ameliorees, attachees de façon stable, de compositions definies presentant diverses fonctions ou specificites de liaison
WO2010022225A1 (fr) * 2008-08-20 2010-02-25 Ibc Pharmaceuticals, Inc. Vaccins d'accostage et de verrouillage « dock-and-lock » (dnl) pour une thérapie contre le cancer

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHANG C-H ET AL: "The Dock and Lock Method: A Novel Platform Technology for Building Multivalent, Multifunctional Structures of Defined Composition with Retain Bioactivity", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 13, no. 18 SUPPL, 15 September 2007 (2007-09-15), pages 5586S - 5591S, XP008123543, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1217 *
FONG L ET AL: "DENDRITIC CELL-BASED XENOANTIGEN VACCINATION FOR PROSTATE CANCER IMMUNOTHERAPY", THE JOURNAL OF IMMUNOLOGY, THE AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 167, 1 January 2001 (2001-01-01), pages 7150 - 7156, XP008065266, ISSN: 0022-1767 *
KIRSHNER JULIA ET AL: "A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma", BLOOD, vol. 112, no. 7, October 2008 (2008-10-01), pages 2935 - 2945, XP002674576, ISSN: 0006-4971 *
KRETZ-ROMMEL ANKE ET AL: "In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, vol. 30, no. 7, 1 October 2007 (2007-10-01), pages 715 - 726, XP009094216, ISSN: 1524-9557 *
ROSSI E A ET AL: "Stably Tethered Multifunctional Structures of Defined Composition Made by the Dock and Lock Method for Use in Cancer Targeting", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, NATIONAL ACADEMY OF SCIENCES, vol. 103, no. 18, 2 May 2006 (2006-05-02), pages 6841 - 6846, XP008123542, ISSN: 0027-8424, [retrieved on 20060424], DOI: 10.1073/PNAS.0600982103 *
See also references of WO2010117984A1 *
TITZER S ET AL: "Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects.", BRITISH JOURNAL OF HAEMATOLOGY MAR 2000 LNKD- PUBMED:10792287, vol. 108, no. 4, March 2000 (2000-03-01), pages 805 - 816, XP002674551, ISSN: 0007-1048 *

Also Published As

Publication number Publication date
WO2010117984A1 (fr) 2010-10-14
EP2416807A1 (fr) 2012-02-15

Similar Documents

Publication Publication Date Title
IL217008A0 (en) Vaccine
EP2429585A4 (fr) Immunothérapie par vaccin
GB0905570D0 (en) Combined vaccines
GB201103481D0 (en) No details
GB201016096D0 (en) No details
ZA201202407B (en) Photobioreactor
GB201016097D0 (en) No details
GB0907413D0 (en) Novel methods
GB201118187D0 (en) Photobioreactor
ZA201109437B (en) Novel azabicyclohexanes
PL2444103T3 (pl) Szczepionka przeciwko rakowi szyjki macicy
PL2464939T3 (pl) Udoskonalony nośnik przedmiotu obrabianego
EP2408473A4 (fr) Procédés de vaccination
ZA201105535B (en) Novel tricyanoborates
GB0914596D0 (en) Improved hatchcover
GB201006165D0 (en) Vaccine
EP2346531A4 (fr) Vaccin antitumoral
GB201003293D0 (en) Cancer vaccine
HK1152951A1 (en) Novel tumor marker
GB0907935D0 (en) Vaccines
IL216102A0 (en) Combined measles-malaria vaccine
EP2498815A4 (fr) Composition de vaccin
GB201000522D0 (en) Vaccine
GB0910751D0 (en) Prostate cancer vaccine
GB0907601D0 (en) Novel methods

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20111108

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 51/00 20060101AFI20120427BHEP

Ipc: C07K 16/28 20060101ALN20120427BHEP

Ipc: C12P 21/08 20060101ALI20120427BHEP

Ipc: A61K 39/00 20060101ALI20120427BHEP

A4 Supplementary search report drawn up and despatched

Effective date: 20120510

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20150507

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20170613